Stay updated with breaking news from Report From. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two new analyses from the DELIVER Phase III trial presented at European Society of Cardiology’s Heart Failure 2023 congress in Prague, Czech Republic support the consistent benefits of Farxiga regardless of heart failure (HF) duration1 and across the spectrum of cardiovascular, renal and metabolic (CVRM) ...
- New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression - --Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism
— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — --Data Further Advances Understanding of VASCEPA/VAZKEPA... | May 12, 2023
AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER ...
FDA approval means patients with heart failure can benefit from FARXIGA regardless of left ventricular ejection fraction status ... | May 9, 2023